GlassScriptPhysician profile
Laura Gutierrez
NPI 1700229432
$4,759.69
in general payments reported to CMS, 2019-2025
27 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,769 · 2020: $397 · 2021: $309 · 2022: $549 · 2023: $510 · 2024: $23.59 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,229.30 | 2019-2023 | Da Vinci Surgical System |
| Abbvie INC. | $569.51 | 2019-2023 | |
| Pfizer INC. | $464.80 | 2019-2023 | |
| Medtronic, INC. | $259.75 | 2022-2023 | V-Loc 180 |
| Bayer Healthcare Pharmaceuticals INC. | $211.08 | 2019-2023 | |
| Ethicon US, LLC | $150.36 | 2020-2023 | Enseal, Vicryl, Vistaseal |
| Avion Pharmaceuticals | $84.78 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $76.10 | 2023 | Breztri |
| Lupin INC. | $74.60 | 2019-2020 | |
| Astellas Pharma US INC | $63.40 | 2025 | Veozah |
| Duchesnay USA Incorporated | $61.23 | 2019 | |
| Evofem Biosciences, INC. | $55.65 | 2022-2023 | Phexxi |
| Avanos Medical | $55.20 | 2025 | On-Q Pump and Accessories |
| Hologic Sales and Service, LLC | $51.38 | 2019-2023 | Omni Hysteroscope, Novasure, Myosure Tissue Removal Device |
| Convatec INC. | $50.80 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $45.95 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $34.18 | 2023-2025 | Slynd |
| Therapeuticsmd, INC. | $32.98 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $31.52 | 2023-2025 | Gemtesa, Myfembree |
| Vertical Pharmaceuticals, LLC | $26.46 | 2019 | |
| Amag Pharmaceuticals, INC. | $23.32 | 2019 | |
| Alydia Health | $22.62 | 2021 | |
| Organon LLC | $22.04 | 2021-2024 | Nexplanon |
| Aspira Women'S Health INC | $16.81 | 2022 | |
| Axonics, INC. | $16.66 | 2022 | |
| Shield Therapeutics INC | $15.45 | 2024 | |
| Bard Access Systems, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.